Prokaryotics is a start-up biotechnology company resulting from licensing several novel antibiotic programs from Merck & Co., Inc. – by a team of former senior scientists at the company including the head of the Antimicrobial Early Discovery Unit, to optimize a number of Merck’s early-stage programs. Prokaryotics has negotiated worldwide rights to develop, manufacture and commercialize pre-clinical assets and programs targeting both Gram-negative and Gram-positive bacteria.

Biotechnology

Pharmaceutical

Prokaryotics

Prokaryotics' headquarters in Union, NJ, United States

Keith Bostian

Brian Burr

Pamela Demain

Holly Sutterlin

Richard Lee

John Tomayko

Lynn Silver

Thomas J. Silhavy

Robert A. Bonomo

David Pompliano

Gerry Wright

The Scientific Advisory Board at Prokaryotics provides expert guidance on scientific strategy, research priorities, and development plans for the company's antibiotic programs. Comprised of seasoned scientists, the board evaluates emerging scientific trends, offers recommendations on optimizing early-stage drug development, and ensures alignment with industry standards and regulatory requirements.

Scientific Advisory Board

This department oversees strategic direction and decision-making for the organization.

Executive Leadership

The Leadership Team at Prokaryotics is responsible for strategic oversight and direction of the company's biotechnology initiatives. Comprising seasoned experts in chemistry and operations, the team drives the optimization of novel antibiotic programs, oversees development and commercialization efforts, and ensures alignment with the company's mission to combat bacterial infections effectively. Their combined expertise fosters innovation, guiding the organization's growth from pre-clinical assets to market readiness.

Leadership Team

This department focuses on advancing scientific knowledge and innovations through research initiatives and experiments.

Research and Development

The Scientific Advisory Team at Prokaryotics, composed of experienced founders and directors in chemistry, microbiology, and operations, provides strategic guidance on optimizing Merck's early-stage antibiotic programs. Their expertise helps shape the development, manufacturing, and commercialization efforts for novel therapies targeting both Gram-negative and Gram-positive bacteria.

Prokaryotics

Org chart

Board & advisors

Teams

Scientific Advisory Board

Executive Leadership

Leadership Team

Research and Development

Scientific Advisory Team

Offices

Prokaryotics

Org chart

Board & advisors

Teams

Scientific Advisory Board

Executive Leadership

Leadership Team

Research and Development

Scientific Advisory Team

Offices

Related companies